Financial Lp Hrt Purchases 64,047 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt acquired 64,047 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average price of $1.51 per share, with a total value of $96,710.97. Following the completion of the transaction, the insider owned 126,993 shares of the company’s stock, valued at approximately $191,759.43. This trade represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, July 10th, Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock. The shares were sold at an average price of $1.40, for a total transaction of $48,913.20.

Bluejay Diagnostics Trading Up 2.5%

Bluejay Diagnostics stock opened at $1.25 on Wednesday. The company has a market cap of $1.29 million, a PE ratio of -0.11 and a beta of 0.88. Bluejay Diagnostics, Inc. has a 1 year low of $1.03 and a 1 year high of $16.68. The company’s 50-day moving average is $2.67 and its two-hundred day moving average is $2.47.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. 18.47% of the stock is owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.